NCT07162181

Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers

Long-Term Safety of Pirtobrutinib in Participants From Study J2N-MC-JZNJ With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

• Status: Active Not Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 13 (estimated)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to find out more about the long-term safety of pirtobrutinib in participants with previously treated types of blood cancer. Participants must have chronic lymphocytic leukemia, small lymphocytic lymphoma, or non-Hodgkins lymphoma. The study is open to those who completed the original study - J2N-MC-JZNJ (NCT04849416) and continue to benefit from treatment. Treatment will be given every 12 weeks and this study is expected to last about 5 years.

Conditions

• Lymphoma, Non-Hodgkin
• Leukemia, Lymphocytic, Chronic, B-Cell
• B-cell Lymphoma

Interventions

Type	Name	Description
DRUG	Pirtobrutinib	Administered orally.

Timeline

• Start date: 2025-08-07
• Primary completion: 2030-05-01
• Completion: 2030-05-01
• First posted: 2025-09-09
• Last updated: 2026-04-17

Locations

6 sites across 1 country: China

Regulatory

• FDA-regulated drug study